Barclays Lowers MetLife (NYSE:MET) Price Target to $89.00

MetLife (NYSE:MET) had its price target cut by investment analysts at Barclays from $92.00 to $89.00 in a research report issued on Wednesday,Benzinga reports. The brokerage presently has an “overweight” rating on the financial services provider’s stock. Barclays‘s price target indicates a potential upside of 19.21% from the company’s current price.

Other research analysts also recently issued research reports about the company. Weiss Ratings downgraded MetLife from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday, March 9th. Wells Fargo & Company decreased their target price on shares of MetLife from $97.00 to $93.00 and set an “overweight” rating on the stock in a report on Wednesday, February 25th. UBS Group boosted their target price on shares of MetLife from $94.00 to $98.00 and gave the company a “buy” rating in a research report on Thursday, February 5th. Morgan Stanley cut their price target on shares of MetLife from $101.00 to $93.00 and set an “overweight” rating for the company in a report on Tuesday, March 3rd. Finally, Keefe, Bruyette & Woods reissued a “moderate buy” rating and issued a $87.00 price objective on shares of MetLife in a research note on Thursday, March 26th. Two equities research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $93.67.

MetLife Trading Up 0.4%

Shares of NYSE:MET opened at $74.66 on Wednesday. The business’s 50 day simple moving average is $73.29 and its 200 day simple moving average is $77.04. MetLife has a 1 year low of $67.33 and a 1 year high of $83.85. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.20 and a quick ratio of 0.20. The company has a market capitalization of $48.68 billion, a P/E ratio of 15.88, a P/E/G ratio of 0.67 and a beta of 0.74.

MetLife (NYSE:MET) last released its earnings results on Wednesday, February 4th. The financial services provider reported $2.49 earnings per share for the quarter, beating analysts’ consensus estimates of $2.34 by $0.15. The firm had revenue of $52.44 billion during the quarter, compared to the consensus estimate of $31.43 billion. MetLife had a return on equity of 21.81% and a net margin of 4.38%.The company’s revenue was up 27.6% compared to the same quarter last year. During the same period in the prior year, the company posted $2.08 EPS. On average, research analysts anticipate that MetLife will post 9.65 EPS for the current fiscal year.

Institutional Investors Weigh In On MetLife

A number of hedge funds and other institutional investors have recently bought and sold shares of MET. Activest Wealth Management raised its position in MetLife by 205.8% in the fourth quarter. Activest Wealth Management now owns 315 shares of the financial services provider’s stock valued at $25,000 after purchasing an additional 212 shares during the last quarter. Vermillion & White Wealth Management Group LLC grew its holdings in shares of MetLife by 790.0% during the third quarter. Vermillion & White Wealth Management Group LLC now owns 356 shares of the financial services provider’s stock worth $29,000 after purchasing an additional 316 shares during the last quarter. Sound Income Strategies LLC increased its stake in shares of MetLife by 58.9% in the fourth quarter. Sound Income Strategies LLC now owns 383 shares of the financial services provider’s stock valued at $29,000 after buying an additional 142 shares during the period. Garton & Associates Financial Advisors LLC acquired a new position in shares of MetLife in the fourth quarter valued at approximately $30,000. Finally, Gunpowder Capital Management LLC dba Oliver Wealth Management bought a new position in MetLife in the 4th quarter valued at approximately $31,000. Institutional investors own 94.99% of the company’s stock.

Key Headlines Impacting MetLife

Here are the key news stories impacting MetLife this week:

• Positive Sentiment: UBS raised its price target on MET to $102 and upgraded the stock to a “buy” (implying ~36% upside from current levels), signaling stronger analyst conviction that can attract buyers. Article Title
• Positive Sentiment: MetLife set its Q1 2026 earnings release for May 6 (call on May 7) and analysts expect double‑digit bottom‑line growth — a near‑term catalyst where an earnings beat could extend the rally. Article Title Article Title
• Neutral Sentiment: Barclays trimmed its price target from $92 to $89 but kept an “overweight” rating — a modestly less bullish view that nonetheless still supports upside, making this a mixed signal for investors. Article Title
• Neutral Sentiment: MetLife Foundation awarded grants to 26 non‑profits across Asia as part of global community programs — positive for ESG/brand but unlikely to move near‑term financials. Article Title
• Neutral Sentiment: World Cup events tied to MetLife Stadium (fan festivals, and reports that Penn Station may partially close during matches) raise short‑term operational/PR headlines tied to the MetLife name but have limited direct impact on corporate earnings. Article Title Article Title

MetLife Company Profile

MetLife, Inc is a global provider of insurance, annuities and employee benefit programs. Headquartered in New York City, the company offers a range of risk protection and retirement solutions to individuals, employers and institutional clients. Its core businesses include life insurance, group benefits, retirement products such as annuities, and supplemental health products including dental and disability coverage.

In addition to traditional life and group insurance, MetLife provides workplace benefits and voluntary products distributed through employer-sponsored programs.